Shots:
- Accord BioPharma’s Hercessi (trastuzumab-strf; 150mg; IV), a biosimilar to Herceptin (trastuzumab), has been approved by the US FDA to treat HER2 overexpressing breast and G/GEJ cancer in the US
- The approval was based on 2 studies incl. P-I (HLX02-HV01 & HLX02-HV02) trial assessing the single-dose, PK equivalence in healthy volunteers. P-III (HLX02-BC01) trial assessing the safety & efficacy in patients with HER2-overexpressing metastatic breast cancer in combination with docetaxel
- Company is also developing HERCESSI in 420mg, FDA decision is expected in Q4’24. In 2021, Shanghai Henlius (originator of Hercessi) granted exclusive development and commercial rights of HERCESSI to Accord in US and Canada
Ref: PR Newswire | Image: Accord Biopharma| Press Release
Related News:- Biogen Receives EMA’s CHMP Positive Opinion for Tofidence (Biosimilar, Roactemra)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
